VRAX revenueFY2026$12.4K
- FY YoY
- +96.2%
- 5Y CAGR
- -36.9%
VRAX revenue was $12.4K for fiscal 2026 (ended Mar 31, 2026), up 96.2% from fiscal 2025. Compound annual growth was -36.9% over 5 years. It rose in 2 of the last 3 fiscal years.
Virax Biolabs Group Limited (VRAX) financials
For fiscal 2026 (ended Mar 31, 2026), Virax Biolabs Group Limited reported $12.4K of revenue and -$5.02M of net income.
- Revenue, FY2026
- $12.4K
- Revenue growth, YoY
- +96.2%
- Net income, FY2026
- -$5.02M
- Net margin
- -40439.1%
- Free cash flow, FY2026
- -$4.88M
- EPS, diluted, FY2026
- -$12.64
- Cash
- $6.44M
- P/S
- 77.05
- Market cap
- $957,238
FY2021FY2026
FY2021FY2026
FY2024FY2026
VRAX revenue and earnings growth
VRAX net incomeFY2026-$5.02M
VRAX net income was -$5.02M for fiscal 2026 (ended Mar 31, 2026), compared with -$6.06M in fiscal 2025.
VRAX EPSFY2026-$12.64
VRAX diluted EPS was -$12.64 for fiscal 2026 (ended Mar 31, 2026).
VRAX free cash flowFY2026-$4.88M
VRAX free cash flow was -$4.88M for fiscal 2026 (ended Mar 31, 2026), compared with -$5.17M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue | $12.4K | $6.3K | $156.4K | $8.6K | $0 | $123.8K |
| Cost of revenue | $4.7K | $59.4K | $105.8K | $9.9K | - | $133.3K |
| Gross profit | $7.7K | -$53.1K | $50.6K | -$1.4K | - | -$9.4K |
| Research and development | $3.74M | $2.03M | $1.61M | $2.18M | $433.7K | $120.2K |
| Selling, general and admin | $2.67M | $3.99M | $4.57M | $3.55M | $1.30M | $457.7K |
| Operating income | -$6.40M | -$6.08M | -$6.53M | -$5.73M | -$1.73M | -$644.5K |
| Pre-tax income | -$5.93M | -$6.20M | -$6.74M | -$5.46M | -$1.75M | -$672.9K |
| Income tax | -$900.2K | -$136.7K | $0 | - | - | - |
| Net income | -$5.02M | -$6.06M | -$6.73M | -$5.46M | -$1.71M | -$651.0K |
| EPS, basic | -$12.64 | -$40.62 | -$83.90 | -$128.25 | -$44.75 | - |
| EPS, diluted | -$12.64 | -$40.62 | -$83.90 | -$128.25 | -$44.75 | - |
| Diluted shares | 397,590 | 149,214 | 80,257 | 42,519.36 | 38,253.04 | 6,325.772 |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $6.44M | $4.23M | $3.59M | $9.35M | $21.8K | $17.6K |
| Inventory | $0 | $94.7K | $60.4K | $0 | $21.0K | $21.1K |
| Current assets | $6.83M | $4.89M | $4.38M | $9.63M | $48.7K | $39.6K |
| Total assets | $8.32M | $6.43M | $5.48M | $9.81M | $48.7K | $39.6K |
| Current liabilities | $685.0K | $673.2K | $168.8K | $908.4K | $1.25M | $871.4K |
| Total liabilities | $989.8K | $964.8K | $345.2K | $908.4K | $1.25M | $871.4K |
| Shareholders' equity | $7.58M | $5.70M | $5.14M | $8.90M | -$1.20M | -$831.8K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.62M | -$4.56M | -$6.40M | -$4.18M | -$809.1K | -$590.2K |
| Capital expenditures | $255.8K | $603.9K | $952.5K | - | - | - |
| Free cash flow | -$4.88M | -$5.17M | -$7.35M | - | - | - |
| Investing cash flow | -$255.8K | -$603.9K | -$1.16M | -$178.4K | - | - |
| Financing cash flow | $7.09M | $5.81M | $1.80M | $13.69M | $813.2K | $585.2K |
| Stock-based compensation | $130.4K | $365.3K | $1.01M | $1.73M | $290.4K | - |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue growth, YoY | 96.2% | -96.0% | 1727.1% | - | -100.0% | - |
| Gross margin | 61.9% | -838.2% | 32.3% | -15.9% | - | -7.6% |
| Operating margin | -51515.2% | -95984.9% | -4171.9% | -66963.7% | - | -520.5% |
| Net margin | -40439.1% | -95739.2% | -4304.8% | -63748.3% | - | -525.8% |
| Free cash flow margin | -39263.6% | -81621.6% | -4698.5% | - | - | - |
| Return on equity | -66.3% | -106.4% | -131.0% | -61.3% | - | - |
| Return on assets | -60.3% | -94.3% | -122.8% | -55.6% | -3508.5% | -1643.0% |
| Current ratio | 9.97 | 7.27 | 25.94 | 10.61 | 0.04 | 0.05 |
Source: XBRL data Virax Biolabs Group Limited files with the SEC, latest filing dated Jul 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 20, 2024; 1-for-25, first reported Jul 6, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
VRAX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VRAX | $12.4K | +96.2% | -$5.02M | -40439.1% | $957,238 |
| IDXX | $4.66B | +11.9% | $1.18B | 25.4% | $55.67B |
| ORKA | - | - | -$152.57M | - | $6.92B |
| LNTH | $1.56B | +2.4% | $269.90M | 17.3% | $6.61B |
| NEOG | $883.99M | -0.3% | -$56.10M | -6.3% | $2.64B |
| CLDX | $158.0K | -93.9% | -$309.06M | -195608.9% | $2.45B |
| NTLA | $52.89M | -8.1% | -$426.14M | -805.7% | $1.70B |
| QDEL | $2.59B | -4.5% | -$369.20M | -14.2% | $829.5M |
| ACHV | - | - | -$114.04M | - | $697.7M |
VRAX FAQ
9 questionsWhat is VRAX revenue?
Virax Biolabs Group Limited (VRAX) reported $12.4K of revenue for fiscal 2026 (ended Mar 31, 2026). That is up 96.2% from the year before.Is VRAX profitable?
No. Virax Biolabs Group Limited reported a net loss of $5.02M for fiscal 2026 (ended Mar 31, 2026).How much cash and debt does VRAX have?
Virax Biolabs Group Limited reported $6.44M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is VRAX revenue growing?
Virax Biolabs Group Limited's revenue changed +96.2% in fiscal 2026, to $12.4K. Its compound annual growth rate was -36.9% over 5 years.What is VRAX gross margin?
Virax Biolabs Group Limited's gross profit was $7.7K on $12.4K of revenue for fiscal 2026 (ended Mar 31, 2026), a gross margin of 61.9%.What is VRAX free cash flow?
Virax Biolabs Group Limited generated -$4.88M of free cash flow for fiscal 2026 (ended Mar 31, 2026), which is operating cash flow of -$4.62M less capital expenditures.What is VRAX earnings per share?
Diluted earnings per share were -$12.64 for fiscal 2026 (ended Mar 31, 2026), from SEC filings, restated for any stock split those filings show.When did VRAX last report financial results?
The latest statements here come from Virax Biolabs Group Limited's 20-F filed on Jul 6, 2026, covering the period ended Mar 31, 2026.Where does this VRAX financial data come from?
Quantisnow builds these statements from the structured XBRL data Virax Biolabs Group Limited files with the SEC. It is provided for information only and is not investment advice.